Chemopreventive Effect of Bitter Melon (Momordica charantia) Juice on Pancreatic Carcinogenesis in LSL‐Kras G12D /+ ; p48 Cre/+ Mice
Molecular Carcinogenesis · 2026
DOI: 10.1002/mc.70164 ↗At a glance
Journal article in Molecular Carcinogenesis, 2026. Written by Lakshmi Sai Pratyusha Bugata and 7 co-authors. Institution: Department of Pharmaceutical Sciences, South Dakota State University, Brookings, South Dakota, USA. Major MEDLINE topics: Momordica charantia, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal. 57 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (original language)
Herein, using the LSL‐Kras G12D/+ ; p48 Cre/+ transgenic mouse model [that recapitulates the full spectrum of human disease, progressing from early pancreatic intraepithelial neoplasia lesions to invasive pancreatic ductal adenocarcinoma (PDAC)], we determined the chemopreventive effect of long‐term (chronic) administration of Bitter Melon Juice (BMJ‐standardized lyophilized juice processed from the fruits of Momordica charantia ) against pancreatic cancer. Starting at 6 weeks of age, female LSL‐Kras G12D/+ ; p48 Cre/+ mice were subjected to BMJ intervention (oral gavage, dose: 200 mg/kg body wt., 5 days/week) for 35 weeks (study end: 41 weeks of age), and pathological and molecular changes in the pancreas were assessed. Results indicated that BMJ shifted the pancreatic tumor profile from moderately differentiated adenocarcinoma in controls towards a more heterogeneous profile enriched for well‐differentiated lesions indicating that prolonged exposure to BMJ bioactives results in a less aggressive phenotype. BMJ significantly reduced proliferative index (~24%) and induced a ~ 4‐fold increase in apoptosis in the pancreas. The effects on AMPK activation (~2‐fold increase) and decrease in the expression of [glucose (GLUT‐1) and lactate (MCT‐4) transporter levels (∼49%–69%,), NF‐κB/p65 (~40%), EMT marker‐Vimentin (~46%), fibrotic microenvironment marker (α‐SMA, ~29%) and Mucin‐1 (MUC‐1, ~45%)] indicate that BMJ modulates several interconnected pathways essential for PDAC growth and progression. Plasma proteomic profiling indicated that Fractalkine (CX3CL1), MIP‐3β (CCL19), MIP‐3α (CCL20), and SCF were decreased by BMJ, while Axl and TNF‐alpha were overexpressed in BMJ‐treated animals compared to positive controls. These results encourage further research into bitter melon compounds as a potential chemopreventive option for pancreatic cancer, especially for high‐risk groups.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmaceutical Sciences, South Dakota State University, Brookings, South Dakota, USA.
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
ORCID profiles: Rama Kant, Chapla Agarwal, Rajesh Agarwal, Komal Raina
Funding
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Bugata, L. S. P., Dhar, D., Kant, R., Kumar, R., Kabir, M. I., Agarwal, C., Agarwal, R., & Raina, K. (2026). Chemopreventive Effect of Bitter Melon (Momordica charantia) Juice on Pancreatic Carcinogenesis in LSL‐Kras G12D /+ ; p48 Cre/+ Mice. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70164
Vancouver
Bugata LSP, Dhar D, Kant R, Kumar R, Kabir MI, Agarwal C, et al. Chemopreventive Effect of Bitter Melon (Momordica charantia) Juice on Pancreatic Carcinogenesis in LSL‐Kras G12D /+ ; p48 Cre/+ Mice. Molecular Carcinogenesis. 2026. doi:10.1002/mc.70164
BibTeX
@article{Bugata2026,
author = {Bugata, Lakshmi Sai Pratyusha and Dhar, Deepanshi and Kant, Rama and Kumar, Robin and Kabir, Md Imtiazul and Agarwal, Chapla and Agarwal, Rajesh and Raina, Komal},
title = {Chemopreventive Effect of Bitter Melon (Momordica charantia) Juice on Pancreatic Carcinogenesis in LSL‐Kras G12D /+ ; p48 Cre/+ Mice},
journal = {Molecular Carcinogenesis},
year = {2026},
doi = {10.1002/mc.70164}
}
EUVIMED